Robin Ross
Retina Specialist · Scottsdale, AZNPI 1114951506
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Amgen at 59.0% of the total. Reporting peaked in 2021 at $3,187 and has fallen 87.7% since, to $391 in 2025. That places this record below the midpoint for retina specialist clinicians in AZ, where the typical reported total is $12,789.
Across 70 payments — averaging $115.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$5K
- Regeneron$1K
- Alimera Sciences, Inc.$474
- Bausch & Lomb Americas Inc.$225
- Oyster Point Pharma, Inc.$186
- Alcon$181
- plus $1K from 15 others
Across 2 payments — averaging $2750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche TCRC, Inc.$6K
What the payments were for
- Consulting fees$1,10014%
- Speaking & faculty fees$4,50056%
- Travel & lodging$260%
- Food & beverage$2,42430%
- Education$180%
- Gifts$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 8 | $4,785 |
| Regeneron | 1 | $1,100 |
| Alimera Sciences, Inc. | 6 | $474 |
| Bausch & Lomb Americas Inc. | 10 | $225 |
| Oyster Point Pharma, Inc. | 5 | $186 |
| Alcon | 8 | $181 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $177 |
| Haag-streit USA, Inc. | 1 | $144 |
| Genentech USA, Inc. | 5 | $128 |
| Tearlab Corp | 1 | $122 |
| Lumibird Medical Inc. | 1 | $113 |
| Biotissue Holdings Inc. | 3 | $78 |
| Apellis Pharmaceuticals, Inc. | 3 | $78 |
| ANI Pharmaceuticals, Inc. | 3 | $72 |
| Carl Zeiss Meditec, Inc. | 1 | $66 |
| Dompe US, Inc. | 2 | $48 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Abbott | 2 | $29 |
| Astellas Pharma US Inc | 1 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Kala Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,107 in reported general payments places this provider in the 40th percentile of 30 retina specialist providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 15 | $26,296 |
| EyleaAflibercept | 14 | $26,230 |
| EysuvisLoteprednol Etabonate | 13 | $6,627 |
| VyzultaLatanoprostene Bunod | 12 | $5,663 |
| Prednisolone Acetate | 28 | $1,020 |
| ErythromycinErythromycin Base | 34 | $414 |
| MoxifloxacinMoxifloxacin Hcl | 17 | $286 |
| Latanoprost | 25 | $202 |
| Timolol Maleate | 17 | $195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Kala Pharmaceuticals, Inc.Eysuvis | $18 | $6,62713 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $225 | $5,66312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 30 retina specialist providers in Arizona.
Other retina specialist in Scottsdale
- Jordan GraffPhoenix$483K
- Rahul ReddyPhoenix$333K
- Henry KwongPhoenix$147K
- Benjamin BakallPhoenix$137K
- Jaime GaitanPhoenix$114K
- Stephen de SouzaPhoenix$95K
- Joseph BryanPhoenix$88K
- Alan GordonPhoenix$86K
- Suhail AlamPhoenix$24K
- Anthony JosephTucson$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.